Briviact® (brivaracetam) – Expanded indication
September 15, 2017 – UCB announced the FDA approval of Briviact (brivaracetam) injection, tablets and oral solution, for the treatment of partial-onset seizures (POS) in patients 16 years of age and older with epilepsy.
Download PDF
